A bispecific chimeric antigen receptor molecule and its application in tumor therapy

一种嵌合抗原受体、特异性的技术，应用在抗肿瘤药、癌抗原成分、抗体医疗成分等方向，达到防止再次复发、强特异性、增强靶向性的效果
CN109503716BActive Publication Date: 2021-04-27CELLYAN THERAPEUTICS WUHAN CO LTD
8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CELLYAN THERAPEUTICS WUHAN CO LTD
Publication Date
2021-04-27

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a bispecific chimeric antigen receptor, which consists of a signal peptide, two specific antigen-binding fragments, an extramembrane spacer, a transmembrane region, and an intracellular co-stimulatory signal region. The specific antigen-binding The first antigen recognized and bound by the fragment is CD19, CD20, CD22, CD33, CD269, CD138, CD79a, CD79b, CD23, ROR1, CD30, B cell surface antibody light chain, CD44, CD123, LewisY, CD7 or CD46 One: the second antigen recognized and bound by the specific antigen-binding fragment is CD38, and the two specific antigen-binding fragments are connected by a linking peptide, and the bispecific chimeric antigen receptor is receptored by constructing a low-affinity chimeric antigen receptor The body and high-affinity chimeric antigen receptors can recognize two tumor-associated antigens respectively with very strong specificity. In addition, the present invention also provides the application of the above-mentioned bispecific chimeric antigen receptor in the treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of cell immunotherapy, in particular to a bispecific chimeric antigen receptor molecule and its application in tumor treatment. Background technique

[0002] With the development of tumor immunology theory and clinical technology, chimeric antigen receptor T-cell immunotherapy (CAR-T) has become one of the most promising tumor immunotherapy. Chimeric antigen receptor CAR consists of a tumor-associated antigen-binding region, an extracellular hinge region, a transmembrane region, and an intracellular signal transduction region. CAR-T cell therapy uses exogenous gene transfection technology to express fusion proteins of single-chain fragment variable (scFv) that recognizes tumor-associated antigens and T cell activation sequences on the surface of T cells, enabling specific recognition of tumor-associated antigens. The scFv of the antigen is coupled to the activation and proliferation signal domain in T cells through t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More